EVALUATING CLINICAL OUTCOMES OVER LONG TERM RESULTS FOR BONE AND SOFT-TISSUE SARCOMAS

Abstract

Background: Despite being rare, sarcomas are very difficult to diagnose and treat, requiring a multidisciplinary 
approach by surgeons, pathologists, radiologists, and/or oncologists. 
Aim: The goals of this clinical trial were to investigate the treatment and prognosis of various sarcomas, including 
Ewing, chondrosarcoma, soft tissue, and osteosarcomas. 
Methods: At baseline, 225 sarcomas' tumour characteristics and the demographics of all research participants were 
recorded. Osteosarcoma and Ewing sarcoma tumour necrosis after surgery was evaluated histopathologically. After 
the material was reviewed, conclusions were made. 
Results: Following a 2-year follow-up, the mean event-free survival and disease survival for osteosarcoma were 46 
(41–53) months and 53 (47–57) months, respectively. The disease-free and overall survival rates for Ewing sarcoma 
in the metastatic group at follow-up were 33.3% (n = 5) and 66.6% (n = 10) respectively. The overall survival rate for 
soft-tissue sarcoma cases was 63.26% (n=31) and 38.77% (n=19) patients at two recall intervals, respectively.  
Conclusion: The current study concluded that chemotherapy results in better clinical outcomes for sarcomas, 
including soft-tissue sarcoma, osteosarcoma, chondrosarcoma, and Ewing sarcoma, taking into account its limitations.